- 1、本文档共70页,可阅读全部内容。
- 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
PI3K/AKT/mTOR 通路在乳腺癌中常过度活化 PI3K/AKT/mTOR 通路在乳腺癌中常过度活化 可能由于1,2 HER2介导的信号上调 PIK3CA突变或扩增 PTEN突变或缺失 PTEN缺失和PIK3CA突变导致 AKT过度活化 PI3K通路信号异常 不可控的细胞代谢增殖和生存 Baselga J. Oncologist. 2011;16(suppl 1):12-19 Agent Target BYL719 P13Kα Ink-1117 P13Kα GDC-0032 P13Kα,δ,? XL-147 Pan-P13k BKM120 Pan-P13k FDC-9041 Pan-P13k PKI-587 Pan-P13k XL-765 P13K/Mtor PF-4691502 P13K/Mtor AZD8055 mTOR(catalytic) INK 128 mTOR(catalytic) MK-2206 AKT1,2,3 GDC-0068 AKT PI3K pathway inhibitors in clinical tials BOLERO-2:PFS PFS HR = 0.38 (95% CI, 0.31-0.48) Log-rank P .0001 Kaplan-Meier medians EVE 10 mg + EXE: 11.0 mo PBO + EXE: 4.1 mo EVE + EXE PBO + EXE Patients at risk 0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 108 485 239 427 179 359 114 292 76 239 56 211 39 166 31 140 27 108 16 77 13 62 9 48 6 32 4 21 1 18 0 11 0 10 0 5 0 0 0 Censoring times EVE 10 mg + EXE (n/N = 188/485) PBO + EXE (n/N = 132/239) 0 20 40 60 80 100 Probability of Event, % Time, wk Patient Population HR+/HER2- locally advanced MBC Post-menopausal AI Resistant No more than 1 prior chemo line allowed for MBC Measurable lesion or bone lesion mTORi naive Adequate amount of tumor tissue for molecular screening(PI3K pathway activation testing) ENTRY RUN IN Fulvestrant 500mg cycle 1 day 1 RANDOMI ZAT ION stratification Visceral Disease PI3K Pathway status BKM120 100mg daily Fulvestrant day 15 cycle 1 and day 1 every cycle N=421 1:1 N=~842 At least 334 PI3K activated Placebo 100mg daily Fulvestrant day 15 cycle 1 and day 1 every cycle N=421 BKM 120.Pivotal Phase III study in Breast Cancer SCREENING PHASE RUN IN TREA TMENT PHASE RANDOMIZED TREATMENT PHASE SAFETY EFFICACY and SURVIVAL FOLLOW UP PHASE Endpoints (patients group) Co-primary PFS(full) PFS (PI3K activated) Co key secondary OS(full) OS(PI3K activated) Secondary PFS, OS (PI3K non-activated/unknown) ORR, CBR (full, PI3K activated, PI3K non-activated/unknown) Safety (full) BKM 120 and fulvestrant PK EORTC QLQ-C30 (full, PI3K activated) Exploratory Biomarkers Lorelei
文档评论(0)